文献速递外周动脉疾病

紫杉醇涂层器械股腘动脉血运重建后长期生存的倾向评分匹配队列分析

Editor's Choice - Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2020-01-08

在慢性肢体威胁性缺血患者中,紫杉醇涂层器械与5年全因死亡(HR 0.83,95%CI 0.77-0.90)、无截肢生存(HR 0.85,95%CI 0.78-0.91)及免于主要心血管事件(HR 0.82,95%CI 0.77-0.89)改善相关;间歇性跛行患者中药物涂层球囊及联合药物洗脱支架与死亡率降低相关。

要点

  • 慢性肢体威胁性缺血患者使用紫杉醇涂层器械与5年生存改善相关。
  • 间歇性跛行患者使用药物涂层球囊或联合药物洗脱支架与死亡率降低相关。
  • 研究期间紫杉醇涂层器械使用比例快速上升。

核心结论

  • 在本大型保险理赔分析中,紫杉醇涂层器械用于慢性肢体威胁性缺血治疗后,长期生存更高、无截肢生存更好且主要心血管事件率更低。

研究设计与样本

  • 排除既往使用紫杉醇涂层器械者以确保首次暴露,按慢性肢体威胁性缺血和间歇性跛行分层,再分为球囊与支架队列,采用倾向评分匹配平衡组间。

主要发现

  • 慢性肢体威胁性缺血患者中,紫杉醇涂层球囊和支架与未涂层器械相比,5年全因死亡HR 0.83(95%CI 0.77-0.90)。
  • 慢性肢体威胁性缺血患者中,无截肢生存HR 0.85(95%CI 0.78-0.91),免于主要心血管事件HR 0.82(95%CI 0.77-0.89)。
  • 间歇性跛行患者中,药物涂层球囊与未涂层器械相比死亡率HR 0.87(95%CI 0.76-0.99),药物涂层球囊联合药物洗脱支架HR 0.88(95%CI 0.80-0.98)。
  • 研究期间紫杉醇涂层器械年使用比例在慢性肢体威胁性缺血患者中从3%升至39%,在间歇性跛行患者中从4%升至48%(均p < .001)。

临床怎么用

  • 对于慢性肢体威胁性缺血患者的股腘动脉血运重建,紫杉醇涂层器械可作为改善长期生存和无截肢生存的选择。
  • 对于间歇性跛行患者,药物涂层球囊或联合药物洗脱支架与死亡率降低相关,可考虑使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to determine the survival of patients after use of paclitaxel coated devices (PCX), as a recent meta-analysis of randomised trials reported higher mortality in patients treated with PCX balloons and stents METHODS: A retrospective health insurance claims analysis of patients covered by the second largest insurance fund in Germany, BARMER, was used to identify index femoropopliteal arterial interventions between 1 January 2010 and 31 December 2018. To ensure first PCX exposure, patients with prior deployment of PCX were excluded. The study cohort was stratified into patients with chronic limb threatening ischaemia (CLTI) and intermittent claudication (IC), then into balloons vs. stents cohorts. Within each stratum PCX were compared with uncoated devices. Propensity score matching was used to balance the study groups. Survival was evaluated using the Kaplan-Meier method and Cox regression. RESULTS: There were 37 914 patients (mean age 73.3 years; 48.8% female) included in the study. The annual proportion of PCX use increased from 3% to 39% during the study period for CLTI and from 4% to 48% for IC (both p < .001). Paclitaxel coated balloons and stents were associated with improved overall survival (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.77-0.90), amputation free survival (HR 0.85, 95% CI 0.78-0.91), and freedom from major cardiovascular events (HR 0.82, 95% CI 0.77-0.89) vs. uncoated devices at five years for CLTI. In IC cohort, mortality was significantly lower after using drug coated balloons (DCB) (HR 0.87, 95% CI 0.76-0.99) or combined DCB and drug eluting stents (HR 0.88, 95% CI 0.80-0.98). CONCLUSION: In this large health insurance claims analysis, rapid adoption of PCX, higher long term survival, better amputation free survival, and lower rates of major cardiovascular events were seen after their use for the treatment of CLTI.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Behrendt CA, Sedrakyan A, Peters F, et al. Editor's Choice - Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis. Eur J Vasc Endovasc Surg. 2020. PMID: 31926836. doi:10.1016/j.ejvs.2019.12.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。